Maker of generic (or off patent) drugs Lupin Ltd, plans to build a portfolio of specialty products for the US market through acquisitions in areas of women’s health, pediatrics and neurology, managing director Nilesh...
Lupin says looking at buyout opportunities in domestic market
Mumbai: After a series of acquisitions in overseas markets over the past two years, Lupin Ltd is looking at buyout opportunities in the domestic market to gain market share, said a top executive. These could be either...
With an aim of expansion, pharma companies like Lupin and Torrent eyeing overseas acquisition
MUMBAI: India’s top pharmaceutical companies are set to embark on an acquisition spree to bulk up their overseas presence. LupinBSE 0.60 %, Torrent, ZydusBSE -0.05 % Cadila, Intas, AurobindoBSE 1.34 %, Dr...
Lupin to buy 21 products of Japan’s Shionogi for Rs 1,000 crore
With 21 new brands, Kyowa will rank sixth amongst generic companies in the country. Kyowa Pharmaceutical Industry, drug major Lupin’s Japanese subsidiary, has inked a pact to acquire 21 products from Shionogi...
Lupin in talks with Japan’s Astellas, Shionogi to buy their off-patent drug brands
MUMBAI: LupinBSE -0.93 %, India’s third-largest drugmaker, is in talks with Japan’s Astellas and Shionogi to buy the off-patent medicine brands they have separately put on the block, two people aware of the...
Torrent, Dr Reddy’s, Aurobindo, Cipla, Lupin in race to buy Sagent.
At least five Indian drug companies — Torrent Pharmaceuticals, Dr Reddy’s Laboratories, Aurobindo Pharma, Cipla and Lupin — are in initial discussions to bid for Sagent Pharmaceuticals, a Nasdaq-listed...
Buy Bajaj Corp, Lupin, LIC Housing: Anand Rathi
LIC HOUSING FINANCE: BUY TARGET: Rs 492 STOP LOOSS: 459 The stock has recently taken multiple support at around Rs 453-456 zones and moving upwards after a consolidation of last 10 trading sessions. It has managed to...
LUPIN ACQUIRES US GENERICS FIRM GAVIS FOR $880 MILLION
Pharma industry is growing very fast mainly through the inorganic route and given below are some major deals in last five years. RanbaxySun TOP PHARMA DEALS IN INDIA Target Acquirer Deal Size ($bn) Year Ranbaxy Daiichi...
ACME looks to sell 35% stake to raise Rs 3,000 crore
ACME Cleantech, the largest independent solar power producer in India, is set to sell about 35% stake in the holding company for about ₹3,000 crore, said multiple people aware of the development. The fundraise, a...
HK’s Gaw Capital in advanced talks to buy Atria stake
Hong Kong’s Gaw Capital Partners is in talks with Atria Power Corp. Pvt. Ltd to acquire a majority stake in the Bengaluru-based firm for an estimated equity value of $250 million, two people familiar with the...
Swiss investment firm to buy majority stake in Sunsure Energy for $400 million
Swiss investment firm Partners Group has agreed to acquire a majority stake in Gurgaon-headquartered renewable energy company Sunsure Energy for $400 million (about ₹3,290 crore). The investment in Sunsure Energy, which...
Keddara, Creador join in race for Tata Capital’s stake in Shriji Polymers
A clutch of private equity funds such as Kedaara Capital, Creador, ChrysCapital and Goldman Sachs have evinced interest to acquire the 13% stake held by Tata Capital Healthcare Fund in Ujjain based Shriji Polymers...